Clinical efficacy of different postoperative drug treatments for patients with stage Ⅳ endometriosis
10.3760/cma.j.cn341190-20241020-01349
- VernacularTitle:Ⅳ期子宫内膜异位症患者术后不同药物治疗效果观察
- Author:
Zhanqiu LIU
1
;
Lingling WANG
1
;
Xiaowen HU
1
Author Information
1. 蚌埠医科大学第一附属医院妇产科，蚌埠 233030
- Publication Type:Journal Article
- Keywords:
Endometriosis;
Estradiol;
Luteinizing hormone;
Follicle stimulating hormone;
Dysmenorrhea;
Fertility;
Comparative effectiveness research
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(12):1835-1839
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of different postoperative drug treatments for patients with stage Ⅳ endometriosis.Methods:A retrospective analysis was conducted on 100 patients with a recent need for fertility who underwent fertility-preserving surgery and were pathologically confirmed to have endometriosis after surgery at the Department of Gynecology of The First Affiliated Hospital of Bengbu Medical University between January 2020 and June 2023. Based on the different adjuvant drugs used for postoperative treatment, the patients were divided into two groups: the leuprolide group and the dienogest group, with 50 patients in each group. The therapeutic effects of the two groups were compared, including changes in sex hormone levels and severity of dysmenorrhea after treatment compared with before treatment. Additionally, pregnancy rate 1 year after surgery and the occurrence of adverse reactions were also monitored.Results:After treatment, the serum levels of estradiol, luteinizing hormone, and follicle-stimulating hormone in the dienogest group were (35.77 ± 6.28) ng/L, (0.50 ± 0.03) IU/L, and (3.90 ± 0.32) IU/L, respectively, and they were (23.36 ± 6.09) ng/L, (0.30 ± 0.02) IU/L, and (2.68 ± 0.28) IU/L, respectively in the leuprolide group. All these measurements were significantly lower than those recorded before treatment in the corresponding group ( t = 40.15, 112.95, 36.25, 27.87, 124.87, 75.86, all P < 0.05). After surgery, the Visual Analog Scale score in the dienogest group was significantly lower than that in the leuprolide group ( t = -11.50, P < 0.05). Within 1 year after surgery, the pregnancy rate in the dienogest group was significantly higher than that in the leuprolide group (χ2 = 3.90, P < 0.05). Conclusion:Compared with postoperative intervention using leuprolide, dienogest as a postoperative drug therapy for patients with stage IV endometriosis demonstrated greater effectiveness in improving fertility and reducing the severity of dysmenorrhea.
